Q-omics provides the consensus-scored TMEM200C profile across patient tissues and cancer cell-line models. TMEM200C expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM200C is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, TMEM200C RNA expression shows 16,074 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, and UVM as cancer lineages where TMEM200C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM200C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM200C survival associations across molecular data types. TMEM200C RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM200C RNA expression–survival associations across cancer types. High TMEM200C expression shows unfavorable associations in KIRP, KIRC, UVM and BLCA, but favorable associations in BRCA and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM200C RNA expression.
This table summarizes TMEM200C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM200C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM200C shows lower tumor expression in KIRP, KICH and BRCA and higher tumor expression in LUAD, LUSC and THCA. The KIRP box plot shows higher TMEM200C RNA expression in normal versus tumor tissue (log2 FC = −0.709, t-test p < 0.001).
This table shows molecular features associated with TMEM200C in patient tissues and cancer cell lines. In patient samples, TMEM200C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM200C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
